Development of budesonide nanocluster dry powder aerosols: Formulation and stability

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3445-3455

  El Gendy, Nashwa ^a,b   Huang, Shan ^a   Selvam, Parthiban ^a   Soni, Pravin ^d   Berkland, Cory ^a,c  

^a UNIVERSITY OF KANSAS   (United States)

^b Beni Suef University   (Egypt)

^c University of Kansas   (United States)

^d PharMarco   (United States)

Author keywords

Aerosols; Attrition; Budesonide; Dry powder; Formulation; Inhalation; NanoClusters; Nanotechnology; Pulmonary drug delivery; Stability

Indexed keywords

BUDESONIDE;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; DRY POWDER; HUMAN; NANOTECHNOLOGY; PHYSICAL CHEMISTRY; POWDER INHALER; REPRODUCIBILITY;

EID: 84864071117     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23176     Document Type: Article

References (35)

1. Timsina M, Martin G, Marriott C, Ganderton D, Yianneskis M. 1994. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 101(1-2):1-13.
2. Aswania O, Ritson S, Iqbal S, Bhatt J, Rigby AS, Everard ML. 2004. Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhalers. J Aerosol Med 17(3):231-238.
3. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. 2000. Inhaled corticosteroids for asthma therapy. Chest 117(2):542-550.
4. Smyth HDC, Hickey AJ. 2005. Carriers in drug powder delivery: Implications for inhalation system design. Am J Drug Delivery 3(2):117-132.
5. Telko MJ, Hickey AJ. 2005. Dry powder inhaler formulation. Respir Care 50(9):1209.
6. Garekani H, Sadeghi F, Badiee A, Mostafa S, Rajabi-Siahboomi AR, Rajabi-Siahboomi A. 2001. Crystal habit modifications of ibuprofen and their physicomechanical characteristics. Drug Dev Ind Pharm 27(8):803-809.
7. Begat P, Morton DAV, Staniforth JN, Price R. 2004. The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm Res 21(9):1591-1597.
8. Hickey A, Gonda I, Irwin W, Fildes F. 1990. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci 79(11):1009.
9. Maggi L, Bruni R, Conte U. 1999. Influence of the moisture on the performance of a new dry powder inhaler. Int J Pharm 177(1):83-91.
10. Hickey A, Fults K, Pillai R. 1992. Use of particle morphology to influence the delivery of drugs from dry powder aerosols. J Biopharm Sci 3(1-2):107-113.
11. Young P, Cocconi D, Colombo P, Bettini R, Price R, Steele D, Tobyn M. 2002. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing." J Pharm Pharmacol 54(10):1339-1344.
12. Zeng XM, Martin GP, Marriott C, Pritchard J. 2001. Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. J Pharm Sci 90(9):1424-1434.
13. Chew NYK, Chan HK. 2002. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 15(3):325-330.
14. Islam N, Stewart P, Larson I, Hartley P. 2004. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci 93(4):1030-1038.
15. Podczeck F. 1998. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. Int J Pharm 160(1):119-130.
16. Ohta M, Buckton G. 2004. Determination of the changes in surface energetics of cefditoren pivoxil as a consequence of processing induced disorder and equilibration to different relative humidities. Int J Pharm 269(1):81-88.
17. Bailey MM, Gorman EM, Munson EJ, Berkland C. 2008. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir 24(23):13614-13620.
18. El-Gendy N, Desai V, Berkland C. 2010. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J Pharm Innovation 5(3):79-87.
19. Hindle M, Byron PR. 1995. Dose emissions from marketed dry powder inhalers. Int J Pharm 116(2):169-177.
20. Murthy T, Priya MBV, Satyanarayana V. 2010. Formulation and evaluation of dry powder inhaler for tiotropium bromide. Int J Innovative Pharm Res 1(1):14-22.
21. Taki M, Marriott C, Zeng XM, Martin GP. 2010. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: A comparison of three impactors. Int J Pharm 388(1-2):40-51.
22. El-Gendy N, Aillon KL, Berkland C. 2010. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm 391(1):305-312.
23. El-Gendy N, Berkland C. 2009. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 26(7):1752-1763.
24. Kumar V, Kothari SH, Banker GS. 2001. Compression, compaction, and disintegration properties of low crystallinity celluloses produced using different agitation rates during their regeneration from phosphoric acid solutions. AAPS PharmSciTech 2(2):22-28.
25. Tougas TP, Christopher D, Mitchell J, Lyapustina S, Van Oort M, Bauer R, Glaab V. 2011. Product lifecycle approach to cascade impaction measurements. AAPS PharmSciTech 12:312-322.
26. Nadarassan DK, Assi KH, Chrystyn H. 2010. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. Eur J Pharm Sci 39(5):348-354.
27. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. 2009. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 369(1-2):136-143.
28. Pornputtapitak W, El-gendy N, Berkland C. 2012. Nanocluster budesonide formulations enhance drug delivery through endotracheal tubes. J Pharm Sci 101(3):1063-1072.
29. El-Gendy N, Pornputtapitak W, Berkland C. 2011. Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. Eur J Pharm Sci 44(4):522-533.
30. Coates MS, Chan HK, Fletcher DF, Raper JA. 2005. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res 22(9):1445-1453.
31. Behara SRB, Larson I, Kippax P, Stewart P, Morton DAV. 2012. Insight into pressure drop dependent efficiencies of dry powder inhalers. Eur J Pharm Sci 46(3):142-148.
32. Coates MS, Fletcher DF, Chan HK, Raper JA. 2005. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res 22(6):923-932.
33. Lechuga-Ballesteros D, Charan C, Stults CLM, Stevenson CL, Miller DP, Vehring R, Tep V, Kuo MC. 2008. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 97(1):287-302.
34. Changsan N, Chan HK, Separovic F, Srichana T. 2009. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 98(2):628-639.
35. Kawabata Y, Aoki Y, Matsui T, Yamamoto K, Sato H, Onoue S, Yamada S. 2010. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats. Eur J Pharm Biopharm 77(1):178-181.